PrimeraDx to Develop Companion Diagnostics Assays for Personalized Medicine

27 Jul 2012
Share
PrimeraDx, a molecular diagnostics company, has announced that it has entered into a multi-year relationship with Eli Lilly and Company to develop diagnostic products in support of multiple clinical development programs for novel therapeutics. Under the terms of this agreement, the two companies will collaborate to develop innovative multiplex assays on PrimeraDx’s clinical platform, the ICEPlex® System.
 
Dr. Matt McManus, President and CEO of PrimeraDx said, “This relationship really moves our company forward in achieving our goals of bringing personalized medicine to the clinic and being the leader in the high-value companion diagnostics space. These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients. We are very excited about collaborating with Lilly on these important programs.”

“We have great expectations of our collaboration with PrimeraDx,” said Dr. Andrew Schade, Senior Director, Clinical Diagnostics Laboratory at Lilly. “The unique ability of the ICEPlex System to combine multiple DNA and RNA biomarkers into a single multiplex assay could prove invaluable in our drive to develop companion diagnostics for crucial assets in our clinical pipeline.

“Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas,” added Schade.

Request Info


Company website

PrimeraDx
profile photo

Sonia Nicholas
Clinical Diagnostics Editor